Subtopic Deep Dive
Cisplatin-Induced Oxidative Stress Nephrotoxicity
Research Guide
What is Cisplatin-Induced Oxidative Stress Nephrotoxicity?
Cisplatin-induced oxidative stress nephrotoxicity is the renal damage in proximal tubules caused by cisplatin-generated reactive oxygen species (ROS), leading to lipid peroxidation and antioxidant enzyme depletion.
Cisplatin triggers mitochondrial ROS production contributing to cytotoxicity, as shown in mouse models (Marullo et al., 2013, 756 citations). This oxidative stress causes acute kidney injury (AKI) via pathways involving TNF-α-mediated inflammation (Ramesh and Reeves, 2002, 751 citations). Over 10 key papers since 2002 document Nrf2 activation and radical scavengers as protective strategies (Özkök and Edelstein, 2014, 678 citations).
Why It Matters
Targeting oxidative stress preserves renal function in 30-50% of cisplatin-treated patients, enabling higher chemotherapy doses for ovarian, lung, and testicular cancers (Manohar and Leung, 2017). Natural products like Nrf2 activators reduce nephrotoxicity in preclinical models without compromising antitumor effects (Fang et al., 2021). Mesenchymal stem cell exosomes mitigate ROS and apoptosis in vivo, offering translation potential (Zhou et al., 2013). Recent reviews highlight biomarkers for early intervention (Tang et al., 2022).
Key Research Challenges
Balancing Renoprotection vs Tumor Toxicity
Antioxidants protect kidneys but may reduce cisplatin's DNA-adduct antitumor efficacy (Volarević et al., 2019). Dose-timing of Nrf2 activators remains unresolved in clinical trials. Achieving selective proximal tubule protection without systemic interference is critical (Tang et al., 2022).
Identifying Reliable Oxidative Stress Biomarkers
Urinary KIM-1 and NGAL correlate with AKI but lack ROS specificity (Holditch et al., 2019). Distinguishing cisplatin-ROS from other nephrotoxins requires validated panels. Mitochondrial redox status assays need clinical standardization (Marullo et al., 2013).
Translating Preclinical Models to Humans
Mouse models overpredict natural product efficacy due to metabolic differences (Fang et al., 2021). Human proximal tubule organoids show variable ROS responses. Scaling exosome therapies faces manufacturing hurdles (Zhou et al., 2013).
Essential Papers
Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions
Rossella Marullo, Erica Werner, Natalya Degtyareva et al. · 2013 · PLoS ONE · 756 citations
Cisplatin is one of the most effective and widely used anticancer agents for the treatment of several types of tumors. The cytotoxic effect of cisplatin is thought to be mediated primarily by the g...
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
Ganesan Ramesh, William Reeves · 2002 · Journal of Clinical Investigation · 751 citations
The purpose of these studies was to examine the role of cytokines in the pathogenesis of cisplatin nephrotoxicity. Injection of mice with cisplatin (20 mg/kg) led to severe renal failure. The expre...
Pathophysiology of Cisplatin-Induced Acute Kidney Injury
Abdullah Özkök, Charles L. Edelstein · 2014 · BioMed Research International · 678 citations
Cisplatin and other platinum derivatives are the most widely used chemotherapeutic agents to treat solid tumors including ovarian, head and neck, and testicular germ cell tumors. A known complicati...
Drug-Induced Oxidative Stress and Toxicity
Damian G. Deavall, Elizabeth A. Martin, Judith Horner et al. · 2012 · Journal of Toxicology · 667 citations
Reactive oxygen species (ROS) are a byproduct of normal metabolism and have roles in cell signaling and homeostasis. Species include oxygen radicals and reactive nonradicals. Mechanisms exist that ...
Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro
Ying Zhou, Huitao Xu, Wenrong Xu et al. · 2013 · Stem Cell Research & Therapy · 660 citations
Cisplatin nephrotoxicity: a review of the literature
Sandhya Manohar, Nelson Leung · 2017 · Journal of Nephrology · 610 citations
Cisplatin is a platinum containing drug first approved as an antineoplastic agent in 1978. It remains an important and effective therapy in many forms of cancer today. Cisplatin mediates its tumorc...
Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity
Vladislav Volarević, Bojana Djokovic, Marina Gazdic et al. · 2019 · Journal of Biomedical Science · 405 citations
Reading Guide
Foundational Papers
Start with Marullo et al. (2013, 756 citations) for mitochondrial ROS mechanisms; Ramesh and Reeves (2002, 751 citations) for cytokine pathways; Deavall et al. (2012, 667 citations) for general drug-ROS toxicity.
Recent Advances
Tang et al. (2022) for therapeutic implications; Fang et al. (2021) on natural products; Holditch et al. (2019) for AKI models and biomarkers.
Core Methods
Mouse cisplatin injection (20 mg/kg) with renal function tests; DCFH-DA for ROS; Nrf2/Western blots; ex vivo proximal tubule assays; urinary NGAL/KIM-1 ELISA.
How PapersFlow Helps You Research Cisplatin-Induced Oxidative Stress Nephrotoxicity
Discover & Search
Research Agent uses citationGraph on Marullo et al. (2013) to map 756-citation mitochondrial ROS pathways, then findSimilarPapers reveals Ramesh and Reeves (2002) TNF-α links and Zhou et al. (2013) exosome protections. exaSearch queries 'cisplatin Nrf2 activators proximal tubule' across 250M+ OpenAlex papers for emerging radical scavengers.
Analyze & Verify
Analysis Agent applies readPaperContent to extract ROS quantification from Özkök and Edelstein (2014), then runPythonAnalysis with pandas/matplotlib to meta-analyze lipid peroxidation data across 10 papers. verifyResponse (CoVe) with GRADE grading scores intervention evidence as moderate for natural products (Fang et al., 2021), flagging low human trial certainty.
Synthesize & Write
Synthesis Agent detects gaps in clinical Nrf2 trials via contradiction flagging between preclinical (Volarević et al., 2019) and review data (Tang et al., 2022), then Writing Agent uses latexEditText/latexSyncCitations for review drafts and exportMermaid to diagram ROS-lipid peroxidation cascades.
Use Cases
"Extract and plot ROS levels from cisplatin nephrotoxicity datasets across Marullo 2013 and Deavall 2012"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas aggregate, matplotlib barplot of mitochondrial ROS by dose) → CSV export of standardized mean differences.
"Write LaTeX review section on exosome protection mechanisms citing Zhou 2013 and Tang 2022"
Synthesis Agent → gap detection → Writing Agent → latexEditText (draft text) → latexSyncCitations (add DOIs) → latexCompile (PDF with figure) → peer review simulation.
"Find GitHub repos analyzing cisplatin oxidative stress models from Holditch 2019"
Research Agent → paperExtractUrls (Holditch et al. 2019) → paperFindGithubRepo → githubRepoInspect (ROS simulation code) → runPythonAnalysis (re-run nephrotoxicity models).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ cisplatin ROS papers, chaining searchPapers → citationGraph → GRADE evidence tables for Nrf2 interventions. DeepScan's 7-step analysis verifies biomarker claims from Ramesh (2002) with CoVe checkpoints and statistical tests. Theorizer generates hypotheses on exosome-ROS interactions from Zhou (2013) and Volarević (2019) abstracts.
Frequently Asked Questions
What defines cisplatin-induced oxidative stress nephrotoxicity?
It involves cisplatin-triggered mitochondrial ROS in proximal tubules causing lipid peroxidation and enzyme depletion, leading to AKI (Marullo et al., 2013).
What are key methods to study it?
Mouse models measure TNF-α/chemokines post-20 mg/kg cisplatin; human studies use urinary biomarkers like KIM-1; in vitro assays quantify mitochondrial redox (Ramesh and Reeves, 2002; Özkök and Edelstein, 2014).
What are the most cited papers?
Marullo et al. (2013, 756 citations) on mitochondrial ROS; Ramesh and Reeves (2002, 751 citations) on TNF-α; Özkök and Edelstein (2014, 678 citations) on AKI pathophysiology.
What open problems remain?
Clinical translation of natural products/Nrf2 activators without antitumor interference; specific ROS biomarkers; organoid models for human relevance (Fang et al., 2021; Tang et al., 2022).
Research Chemotherapy-induced organ toxicity mitigation with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cisplatin-Induced Oxidative Stress Nephrotoxicity with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers